临床医生对多发性骨髓瘤中可测量残留病的态度和实践。 - Suppr | 超能文献

Clinician attitudes and practices toward measurable residual disease in multiple myeloma.

作者信息

Derman Benjamin A, Jasielec Jagoda K, Jakubowiak Andrzej J

机构信息

Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.

出版信息

Br J Haematol. 2020 Aug;190(3):470-472. doi: 10.1111/bjh.16805. Epub 2020 Jun 7.

DOI:10.1111/bjh.16805

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Clinician attitudes and practices toward measurable residual disease in multiple myeloma.临床医生对多发性骨髓瘤中可测量残留病的态度和实践。

Br J Haematol. 2020 Aug;190(3):470-472. doi: 10.1111/bjh.16805. Epub 2020 Jun 7.

2

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.采用流式细胞术检测多发性骨髓瘤微小残留病：存在显著异质性。

Blood. 2013 Aug 8;122(6):1088-9. doi: 10.1182/blood-2013-05-506170.

3

Measurable Residual Disease and Decision-Making in Multiple Myeloma.多发性骨髓瘤的可测量残留疾病与决策。

Hematol Oncol Clin North Am. 2024 Apr;38(2):477-495. doi: 10.1016/j.hoc.2023.12.009. Epub 2024 Jan 6.

4

MRD Assessment in Multiple Myeloma: Progress and Challenges.多发性骨髓瘤中的微小残留病灶评估：进展与挑战。

Curr Hematol Malig Rep. 2021 Apr;16(2):162-171. doi: 10.1007/s11899-021-00633-5. Epub 2021 May 5.

5

Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.多发性骨髓瘤中可测量残留病评估的挑战与机遇。

Br J Haematol. 2019 Sep;186(6):807-819. doi: 10.1111/bjh.16130. Epub 2019 Jul 31.

6

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.对比基于 MALDI-TOF 质谱分析的外周血和骨髓流式细胞术用于多发性骨髓瘤患者微小残留病灶的检测。

Br J Haematol. 2020 Jun;189(5):904-907. doi: 10.1111/bjh.16443. Epub 2020 Feb 5.

7

Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.多发性骨髓瘤中的微小残留病：临床试验中的重要工具。

Rev Recent Clin Trials. 2022;17(1):9-10. doi: 10.2174/1574887116666211123092915.

8

Molecular Diagnostics of Plasma Cell Neoplasms.浆细胞肿瘤的分子诊断。

Surg Pathol Clin. 2023 Jun;16(2):401-410. doi: 10.1016/j.path.2023.01.005. Epub 2023 Mar 10.

9

Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.侵袭性和髓外浆细胞骨髓瘤可逃避骨髓流式细胞术微小残留病检测。

Br J Haematol. 2016 Jun;173(6):947-9. doi: 10.1111/bjh.13655. Epub 2015 Oct 12.

10

[Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].[新一代流式细胞术与新一代测序在多发性骨髓瘤微小残留病评估中的比较]

Zhonghua Xue Ye Xue Za Zhi. 2023 Apr 14;44(4):328-332. doi: 10.3760/cma.j.issn.0253-2727.2023.04.011.

引用本文的文献

1

Knowledge, attitude and practice towards multiple myeloma among medical staff in Enshi Region.恩施地区医务人员对多发性骨髓瘤的知识、态度和实践

Sci Rep. 2025 Jan 27;15(1):3406. doi: 10.1038/s41598-025-88079-0.

2

Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma.关于多发性骨髓瘤中可测量残留病指导下决策的临床医生调查。

Blood Cancer J. 2022 Jul 11;12(7):108. doi: 10.1038/s41408-022-00705-6.